OncoMatch/Clinical Trials/NCT05636111
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Is NCT05636111 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Paclitaxel and Bevacizumab for ovarian cancer.
Treatment: Paclitaxel · Bevacizumab · Lurbinectedin — To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any anticancer therapy
Exception: adjuvant/neoadjuvant therapy permitted if completed >2 weeks before cycle 1 day 1
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤2 weeks prior to cycle 1 day 1
Cannot have received: investigational drug
Use of an anti-cancer treatment drug or investigational drug during the last 28 days or 5 half-lives (whichever is shorter) prior to cycle 1 day 1. A minimum of 10 days between termination of prior treatment and administration of study treatment is required.
Cannot have received: investigational anti-cancer study
Participation in an investigational anti-cancer study within 3 weeks prior to Cycle 1 Day 1
Cannot have received: concurrent anticancer therapy
Exception: steroids allowed
Concurrent therapy with approved or investigational anticancer therapeutic other than steroids.
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dL; ANC >1500/mm3; Platelet count ≥100 x 10^9/L
Kidney function
Measured or calculated creatinine clearance >40 mL/min (Cockcroft-Gault or 24-hour urine collection)
Liver function
Serum bilirubin ≤1.5 x ULN (Gilbert's syndrome exception); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN.
Cardiac function
Unstable cardiovascular function excluded: ECG abnormalities requiring treatment, CHF NYHA Class ≥3, MI within 3 months
Adequate normal organ and marrow function as defined below. Unstable cardiovascular function: ECG abnormalities requiring treatment, or congestive heart failure (CHF) of NYHA Class ≥3, or myocardial infarction (MI) within 3 months.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05636111 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any anticancer therapy, investigational drug, investigational anti-cancer study disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages